Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids
- Özlem Gögebakan1,2,
- Janin Andres1,
- Katrin Biedasek1,
- Knut Mai1,
- Peter Kühnen3,
- Heiko Krude3,
- Frank Isken1,2,
- Natalia Rudovich2,
- Martin A. Osterhoff1,2,
- Ulrich Kintscher4,
- Michael Nauck5,
- Andreas F.H. Pfeiffer1,2 and
- Joachim Spranger1⇓
- 1Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany
- 2German Institute of Human Nutrition Potsdam-Rehbrücke, Department of Clinical Nutrition, Nuthetal, Germany
- 3Charité-Universitätsmedizin Berlin, Campus Virchow, Department of Experimental Pediatric Endocrinology, Berlin, Germany
- 4Charité-Universitätsmedizin Berlin, Center for Cardiovascular Research, Institute of Pharmacology, Berlin, Germany
- 5Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany
- Corresponding author: Joachim Spranger, .
Ö.G., J.A., A.F.H.P., and J.S. contributed equally to this work.
Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to have direct effects on nonislet tissues. GIP also reportedly increased glucose uptake and inhibition of lipolysis in adipocytes after inhibition of the intracellular cortisone-cortisol shuttle 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). We here analyzed whether GIP modifies lipid metabolism and further elucidated the relation between GIP, 11β-HSD1, and fatty acid metabolism. GIP reduced activity of 11β-HSD1 promoter constructs and the expression and activity of 11β-HSD1 in differentiated 3T3-L1 adipocytes in a time- and dose-dependent fashion. This was paralleled by a reduction of free fatty acid (FFA) release and a reduced expression of key enzymes regulating lipolysis in adipose tissue. Preinhibition of 11β-HSD1 completely abolished GIP-induced effects on FFA release. To investigate the acute effects of GIP in humans, a randomized clinical trial was performed. GIP lowered circulating FFAs compared with saline control and reduced expression and ex vivo activity of 11β-HSD1 and adipose triglyceride lipase expression in subcutaneous fat biopsies. Our data suggest that GIP reduces FFA release from adipose tissue by inhibition of lipolysis or by increased reesterification. This process appears to depend on a modification of 11β-HSD1 activity. In general, the presented data support that GIP has direct and insulin-independent effects on adipose tissue.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0902/-/DC1.
- Received July 8, 2010.
- Accepted November 1, 2011.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.